Exclusive License

Related by string. * exclusives . Exclusives . EXCLUSIVES . EXCLUSIVE : EXCLUSIVE AUDIO CONTENT MEMBER . EXCLUSIVE INSIDER DOT NET . EXCLUSIVE AUDIO SHOWS MESSAGE . Exclusive Crews readying / licenses . Licenses . LICENSE . LICENSES : specialty license plates . DRIVING WHILE LICENSE REVOKED . license plate . license plates * Exclusive License Agreement . Obtains Exclusive License *

Related by context. All words. (Click for frequent words.) 76 Patent Covering 74 Develop Novel 72 Files IND 72 Receives Milestone Payment 72 Awarded Qualifying Therapeutic 71 Obtains Exclusive License 71 Small Molecule 70 Milestone Payments 70 Systemic Delivery 70 Patents Covering 70 Receives Patent 70 Milestone Payment 70 Files Patent Application 70 Monoclonal Antibody 70 Drug Candidate 69 Licenses Novel 68 Announces License Agreement 68 Acquires Exclusive 68 Fast Track Status 68 Receives Orphan Drug Designation 68 Present Preclinical Data 68 Issued Patent 68 Announces Issuance 68 Patent Broadly Covering 68 Announce Collaboration Agreement 68 Announce License Agreement 68 Commercialize 68 Collaborators Present 68 Presents Preclinical Data 68 Completes Patient Enrollment 68 Initiates Clinical Trial 67 Initiates Phase II 67 Initiates Clinical 67 Licensing Deal 67 Exclusive License Agreement 67 Testosterone Gel 67 Signs Option Agreement 67 Patent Issued 67 Submits Application 67 BioSante Pharmaceuticals Announces 67 Obtains License 67 Announces FDA Clearance 67 GRAS Status 67 Immunomedics Announces 67 Identifies Potential 67 Miraculins Announces 67 Exercises Option 67 Announces Initiation 66 Submits NDA 66 Initiates Dosing 66 Reacquires 66 Conditional Approval 66 RNAi Therapeutics 66 Announces Licensing Agreement 66 Patents Issued 66 Receives Orphan Drug 66 Taro Receives 66 Sign Licensing Agreement 66 Achieves Milestone 66 Smallpox Vaccine 66 Announce Merger Agreement 66 Begin Clinical Trials 66 Announce Licensing 66 Aptamer 66 FDA Clears 66 Researchers Identify 66 Files Provisional 66 Subsidiary Enters 66 Signs Licensing Agreement 65 NDA Submission 65 Tumor Targeting 65 Biomarker Study 65 Executes Agreement 65 Receives Approvable Letter 65 Anti CD# Antibody 65 Vaccine Adjuvant 65 Avian Flu Vaccine 65 Completes Enrollment 65 Reports Preclinical Data 65 Closes Financing 65 Commercialize Novel 65 Initiates Phase III 65 Scientists Identify 65 Prostate Cancer Vaccine 65 Completes Reverse Merger 65 Enters Into Agreement 65 Meets Primary Endpoint 65 Phase III Clinical Trial 65 Patent Infringement Litigation 65 Diagnostic Tests 65 Phase 2b Clinical Trial 65 Receives FDA Clearance 65 Cross License Agreement 65 Exclusive Licensing Agreement 65 Collaborators Publish 65 Gout Drug 64 Scientists Develop 64 Receive Milestone Payment 64 Patient Enrollment 64 Researchers Develop 64 Initiate Clinical Trial 64 IND Application 64 Expand Collaboration 64 Therapeutic Antibody 64 Epilepsy Drug 64 Secures Financing 64 Commences Phase 64 Sign License Agreement 64 FDA Approvals 64 Recombinant Protein 64 FDA Accepts 64 Receives Conditional 64 Embryonic Stem Cells 64 Granted Orphan Drug 64 Seasonal Influenza Vaccine 64 Mylan Receives Approval 64 Generic Version 64 Begins Shipment 64 Licensing Agreements 64 Presents Positive 64 Completes Financing 64 Completes Dosing 64 Clinical Trial Results 64 Initiates Clinical Trials 64 Successfully Completes Phase 64 Provides Update Regarding 64 Mutually Agree 64 Receives Favorable 64 Preclinical Data 64 Closes Private Placements 64 Anti Tumor 64 Ichor Medical Systems 64 Receives Funding 64 Vaccine Adjuvants 64 Anti Tumor Activity 64 Psoriasis Drug 64 Private Placement Closed 64 Announces Definitive Agreement 64 Antibody Discovery 64 Submits Biologics License Application 64 Biotech Firm 64 Commence Phase 64 Receives Notification 64 SBIR Grant 64 Achieves Significant 64 Initiates Enrollment 63 FDA Okays 63 Novel Antibiotic 63 Licensing Agreement 63 Expanded Indication 63 Metabolic Disease 63 Milestone Payment From 63 Investigational Treatment 63 Study Validates 63 Enrolls First 63 Molecular Diagnostic Test 63 FDA Clearance 63 Regulatory Clearance 63 Oral Calcitonin 63 Teva Provides Update 63 FDA Orphan Drug 63 Develops Novel 63 Lupus Drug 63 Earns Milestone Payment 63 Successfully Completed 63 Ebola Vaccine 63 Enters Into License Agreement 63 Begins Dosing 63 Phase 2a Trial 63 Novel Therapeutic 63 Researchers Uncover 63 Submits Response 63 Study Demonstrates 63 Completes Initial 63 Shows Promise 63 Topical Treatment 63 Misonix Announces 63 Announces Granting 63 Patent Infringement Lawsuit 63 Receives Confirmation 63 Arthritis Drug 63 Valortim TM 63 Provides Updates 63 Recombinant Human 63 Terminates Agreement 63 Demonstrates Ability 63 Tyrosine Kinase Inhibitor 63 Closes Private Placement 63 First Patient Treated 63 Acquire Assets 63 Malaria Vaccine 63 Schizophrenia Drug 63 Biosensor System 63 Licensing Pact 63 Awarded Patent 63 Settle Patent Litigation 63 entitled Compositions 63 Settles Litigation 63 Commercialization Agreement 63 Stem Cell Treatment 63 Announces Termination 63 Announces Cancellation 63 Enters Into Collaboration 63 Receives Notice 63 Announce Commencement 62 Patented Technology 62 Signs LOI 62 TRANSDUR ™ 62 Patent Infringement Case 62 Files Patent 62 Holds Promise 62 Therapeutic Competitors Companies 62 Improves Survival 62 Flamel Technologies Announces 62 Receives CE Marking 62 exclusive sublicense 62 Confirms Efficacy 62 Receives Fast Track 62 Cervical Cancer Vaccine 62 Submits IND 62 Novel Oral 62 Phase 2b Trial 62 Obtains Exclusive Rights 62 Extends Collaboration 62 Secures Funding 62 Complete Merger 62 Lung Cancer Drug 62 HSR Waiting Period 62 Rheumatoid Arthritis Drug 62 Signs Agreements 62 AnaSpec Introduces 62 Sublicense 62 Scientists Uncover 62 Cancer Vaccine 62 Protein Synthesis 62 Osteoporosis Drug 62 Prolongs Survival 62 Receives Unsolicited 62 Enters Negotiations 62 Patient Enrolment 62 Signs Binding Letter 62 First Patient Dosed 62 siRNA Delivery 62 Patent Infringement Suit 62 DOR BioPharma Announces 62 Transdermal Drug 62 Closes Second Tranche 62 Completes Private Placement 62 Amends Agreement 62 Non Invasive 62 Nanoemulsion 62 Drug Shows Promise 62 Enters Agreement 62 Transdermal Patch 62 Patent Lawsuit 62 Influenza Vaccine Production 62 Detection Device 62 RNAi Therapeutic 62 Brain Cells 62 Discontinues 62 Announce Licensing Agreement 62 Biologics Manufacturing 62 Demonstrates Positive 62 Investigational Compound 62 Orphan Status 62 Novel Compounds 62 Bioartificial Liver 62 Tumor Targeted 62 Enters Into Definitive 62 WaferGen Announces 62 Phase IIb Trial 62 Announce Collaboration 62 Signs License Agreement 62 Completes Tender Offer 62 Patent Dispute 62 Generic Version Of 62 First Patient Enrolled 62 Anticancer Agent 62 Blood Pressure Drug 62 Tumor Cells 61 Study Indicates 61 Terminate Merger Agreement 61 License Option Agreement 61 Patent Infringement Suit Against 61 Develop Next Generation 61 Secures Additional 61 Receives Complete Response 61 Announces Publication 61 CysDisplay R 61 Uses Thereof 61 Regenerative Cells 61 Investigational Agent 61 Receives Regulatory 61 Patients Treated With 61 Captisol ® 61 ASX BLT 61 Antisense Drug 61 Receives Approval 61 Receives Positive 61 NeutroPhase TM 61 Updates Status 61 Secures Patent 61 DNA Methylation 61 Naturally Occurring 61 Nicotine Vaccine 61 Novel Vaccine 61 Therapeutic Competitors Report 61 Antibody Drug Conjugate 61 Intellectual Property Portfolio 61 Presents Preclinical 61 Less Invasive 61 Phase IIb Clinical Trial 61 Demonstrates Significant 61 Therapeutic Discovery 61 product platforms AZX# 61 Obtains Approval 61 Therapeutic Vaccine 61 WorldHeart Announces 61 IND Filing 61 Strengthens Balance Sheet 61 Bird Flu Vaccine 61 DARA logo 61 Cholesterol Lowering Drug 61 Enters Into Licensing Agreement 61 Initiates Phase 61 Taglich Brothers Initiates Coverage 61 Daxor Announces 61 Gets FDA Clearance 61 Novel Method 61 Key Milestones 61 Receives Commitment 61 Enters Into Exclusive 61 Files Shelf Registration Statement 61 VIVUS Announces 61 Anthrax Vaccine 61 Nanophase Announces 61 JAK2 Inhibitor 61 Reports Receipt 61 Immune Responses 61 Commercializes 61 Regains Full 61 Genes Involved 61 Phase III Trial 61 Neural Stem Cell 61 Presents Positive Preclinical 61 Lentiviral 61 Receives SFDA Approval 61 Carbon Nanotube Based 61 Receives Favorable Ruling 61 Quark Biotech 61 Initiates Phase 2b 61 Single Dose 61 Orphan Drug Status 61 Cancer Treatments 61 Board Authorizes 61 Cell Differentiation 61 Develop Innovative 61 Vigorously Defend 61 pralatrexate injection folate analogue 61 Vascular Inflammation 61 Wins Approval 61 Enrolling Patients 61 Vaccine Candidate 61 Announce Completion 61 Collaboration Agreement 61 Consummates 61 Clinical Trial Evaluating 61 Phase 1b Clinical Trial 61 Receives Permit 61 Private Placement Financing 61 Obtains Exclusive 61 Announce Settlement 61 Optical Sensors 61 Antigen Specific 61 Accelerate Commercialization 61 InNexus Biotechnology 61 Humanized Anti 61 Protease Inhibitor 61 Shows Promising 61 Clinical Study Shows 61 Announces Tentative Approval 61 Adipose Derived Stem Cells 61 Pandemic Influenza Vaccine 61 Effectively Treats 61 Announces Successful Completion 61 Lorus Therapeutics Announces 61 Patent Infringement Lawsuit Against 61 Study Confirms 61 Clinical Evaluation 61 Submits Supplemental 60 Rotavirus Vaccine 60 Migraine Drug 60 Contrast Enhanced 60 Definitive Merger Agreement 60 Significantly Improves 60 Polymeric 60 Ceragenix 60 Microfluidic Devices 60 Mouse Model 60 Antiviral Drugs 60 Seeks Approval 60 SFDA Approval 60 Kinase Inhibitors 60 Cell Proliferation 60 Immune Cells 60 Announces Dismissal 60 Replacement Therapy 60 Kinase Inhibitor 60 AVANIR Pharmaceuticals Announces 60 Finalizes Acquisition 60 Inhaled Insulin 60 Alnylam Nasdaq ALNY 60 STERIS Corporation Announces 60 Patent Lawsuit Against 60 BioElectronics Corporation Announces 60 Imaging Technique 60 Molecular Profiling 60 Exclusive Distribution 60 Signs Definitive 60 Helps Predict 60 Voluntarily Withdraw 60 Terminates Merger Agreement 60 Summarizes 60 Synthetic Peptide 60 ARRY # 60 Enter Into 60 Protein Expression 60 DermTech International 60 Obtains Patent 60 Jointly Announce 60 Pending Acquisition 60 Asthma Treatment 60 Genetic Tests 60 ddRNAi 60 Completes Second Tranche 60 DIAGNOS Announces 60 InterfeRx 60 Terminates Contract 60 Announces Definitive Agreements 60 Testosterone Patch 60 Treating Chronic 60 Announces Favorable 60 Study Evaluating 60 Gene Mutation 60 Anticancer Compound 60 Announces Private Placement 60 Drug Resistant 60 Awarded Patents 60 Provides Shareholder 60 Completes Asset 60 Oligonucleotide 60 Silicone Breast Implants 60 Announces Signing 60 Stem Cell Patents 60 Demonstrates Potential 60 Finalizes Agreement 60 Novel Inhibitor 60 AVI BioPharma Announces 60 Progenitor Cell 60 Preclinical Study 60 Endothelial Cells 60 Shows Statistically Significant 60 Anticancer Drug 60 Osteoporosis Treatment 60 Wound Dressing 60 Arriva Pharmaceuticals 60 Pivotal Study 60 Significantly Improved 60 Bradmer Pharmaceuticals 60 Novel Protein 60 Nutra Pharma Announces 60 Flagship Product 60 Successful Completion 60 Patent Reexamination 60 Announce Agreement 60 Tuberculosis Vaccine 60 Million Milestone Payment 60 FDA Approval 60 Subsidiary Receives 60 Study Sheds Light 60 Shows Promise Against 60 Protein Polymer Technologies 60 Weight Loss Drug 60 Breast Cancer Cells 60 Device Maker 60 OTCBB IMUC 60 Fortical ® 60 Neural Stem Cells 60 Enters Into Letter 60 Exclusive Licensee 60 Board Unanimously Rejects 60 VentiRx Pharmaceuticals 60 USOTC SSWC 60 Announce Receipt 60 rxRNA 60 Immune Therapy 60 Signs Joint Venture 60 Conjugate 60 Grants Awarded 60 License Pact 60 Expands Scientific Advisory 60 Files Investigational 60 Interferon Gamma 60 Mimetics 60 Announces Commencement 60 Induced Pluripotent Stem Cells 60 Closes Merger 60 Supplemental Biologics License Application 60 Blood Clotting 60 PDUFA Date 60 Successfully Treated 60 Restructures Debt 60 Immune Cell 60 Gene Silencing 60 Being Studied 60 Prometheus Laboratories 60 Announces Receipt 60 Wins Patent Infringement 60 Final Approval 60 Pafuramidine 60 ORADUR ® 60 Extends Tender Offer 60 Metastatic Melanoma 60 Intravascular 60 Gold Nanorods 60 Attorneys Fees 60 Advanced Melanoma 60 Inovio Pharmaceuticals 60 Approve Merger 60 Receptor Agonist 60 Enters Into Joint Venture 60 Regulatory Approval 60 Has Commenced 60 Early Diagnosis 60 Proves Effective 60 Handok Pharmaceuticals 60 Breast Cancer Recurrence 60 Small Molecule Drug 60 Acquire Controlling Interest 60 Non Invasive Treatment 60 Successfully Tested 60 EMD Biosciences Inc. 60 Crowflight Announces 59 Sign Definitive Agreement 59 Receives NASDAQ 59 Exploit collaboration 59 Demonstrates Efficacy 59 Nasdaq Delisting Notice 59 Receives Conditional Approval 59 rPA Anthrax Vaccine 59 Japanese Encephalitis Vaccine 59 Drug Combo 59 Nereus Pharmaceuticals 59 FDA Approves 59 Anti Inflammatory Drug 59 Provides Clarification 59 Proves Successful 59 Drug Fails 59 Protiva Biotherapeutics 59 Oral Mucositis 59 Prodrug 59 Previously Announced Private Placement 59 Immunotherapeutic 59 Gene Variants 59 Achieves Primary Endpoint 59 Regulatory Approvals 59 Aurora Kinase 59 Study Identifies 59 Further Validates 59 Injunction Against 59 Enters Into Definitive Agreement 59 BiTE Antibody 59 Preliminary Injunction Against 59 Pharmaceuticals Initiates 59 Combination Therapy 59 Tissue Engineered 59 Regains Compliance With 59 Intravenous Formulation 59 Diabetic Ulcers 59 Cenomed 59 Significantly Expand 59 Magnetic Nanoparticles 59 Significantly Increases 59 Previously Announced 59 Vicor Technologies Announces 59 Medicure Announces 59 Single Molecule 59 PROT Announces 59 Patent License Agreement 59 Amend Merger Agreement 59 Avian Influenza Vaccine 59 Increases Ownership 59 Galenea 59 Announces Effective Date 59 Generic Versions 59 Endovascular Treatment 59 Dry Powder Inhaler 59 Phosphorescent OLED Lighting 59 Novel Mechanism 59 Well Tolerated 59 Derma Sciences Announces 59 Antisense Oligonucleotides 59 Seikagaku Corporation 59 Test Detects 59 Warrants Exercised 59 Nasdaq HALO 59 vivo fluorescence imaging 59 Reports Positive 59 Therapeutic Vaccines 59 Diabetic Foot Ulcer 59 Smooth Muscle 59 Fungal Infections 59 Regains Compliance 59 Updates Shareholders 59 Beta Blocker 59 Gene Expression Analysis 59 Inks Licensing Deal 59 Quaterra Announces 59 Proven Effective 59 Brain Metastases 59 Pediatric Exclusivity 59 Submits Proposal 59 Receives Tentative FDA 59 Voluntarily Withdraws 59 Dendritic Cells 59 Exclusive Licensing 59 Pivotal Phase III 59 Antigens 59 Headwaters Incorporated Announces 59 Inhibits 59 Radiation Induced 59 Nuclear Receptors 59 Announce Signing 59 Cocaine Addiction 59 Receives Accreditation 59 Amends Terms 59 Tentative Approval 59 Signs Definitive Agreement 59 Lanthanum Carbonate 59 Detect Cancer 59 Nano Scale 59 Explore Strategic Alternatives 59 Anti Inflammatory 59 microRNA Therapeutics 59 Study Proves 59 Announce Definitive Agreement 59 Permanent Injunction Against 59 Electroporation 59 Stent Coating 59 Subsidiary Enters Into 59 Hip Prosthesis 59 Completes Drilling 59 Gene Variant 59 Government Qualifying Therapeutic 59 Obtains CE Mark 59 Antibiotic Treatment 59 Enters Into Negotiations 59 Closes Sale 59 Appears Safe 59 Positive Opinion 59 Romios Announces 59 Crucell Announce 59 Announces Shareholder Approval 59 Blood Thinner 59 Monetizes 59 Antitumor Activity 59 FDA Panel Recommends 59 Diabetic Neuropathy 59 DispersinB R 59 Licenses Patents 59 Acquire Remaining 59 Molecular Diagnostic 59 Immune Mediated 59 Ovarian Cancer Treatment 59 Successfully Treats 59 Receives Tentative Approval 59 SABER ™ 59 Molecular Mechanism 59 Closes Oversubscribed 59 Commercially Available 59 Enters Into Agreements 59 Expands Scope 59 Neuroprotection 59 EMD Biosciences 59 Phase IIa Clinical Trial 59 Files Formal 59 BIOTECHNOLOGY SOURCE 59 FY# Loss Widens 59 Photovoltaic Module 59 Closes Previously Announced 59 Non Brokered Financing 59 Announces Proposed Acquisition 59 HuCAL GOLD R 59 Cholesterol Drug 59 Contrast Agent 59 Announces Non Brokered 59 Results Confirm 59 Expedited Review 59 Confirmatory Phase 59 Significant Milestone 59 Treatment Reduces 59 OTCBB IGXT 59 Bone Metastases 59 Closes Acquisition 59 Improve Survival 59 Initiate Phase 59 Spins Out 59 Efficacy Trial 59 Resubmits 59 Signs MOU 59 Successfully Concludes 59 Drill Permits 59 JAK Inhibitor 59 Orphan Designation 59 Protein Biomarker 59 Finalizes Purchase 59 NASDAQ Deficiency Notice 59 Announce Expiration 59 Launches Generic Version 58 Legal Dispute 58 Completes Merger 58 Therapeutic Efficacy 58 Signs Merger Agreement 58 Clinical Outcome 58 Secures Exclusive 58 Panel Nixes 58 Nasdaq Deficiency Notice 58 ProChon Biotech 58 Pathogen Detection 58 Internationally Recognized 58 Drug Coated Stent 58 Soft Tissue Sarcoma 58 Spinal Implant 58 MEK Inhibitor 58 Completes Previously Announced 58 Clinical Efficacy 58 Initiate Phase III 58 Biotherapeutic 58 Fast Track Designation 58 Ercole Biotech 58 Finalize Agreement 58 Proxy Proposals 58 Jointly Develop 58 Universal Flu Vaccine 58 Announces Debt Settlement 58 Patent Suit 58 Phase III Trials 58 Molecular Mechanisms 58 developing biomedical countermeasures 58 Drilling Underway 58 Acacia Subsidiary 58 Technological Advances 58 Announces Positive 58 Receives Clearance 58 Imaging Techniques 58 Circulating Tumor Cells 58 Combination Treatment 58 Grants Options 58 Files Patent Infringement 58 Virus Infection 58 Minimally Invasive Treatment 58 OTC MNDP 58 Transcept Pharmaceuticals 58 Product Designation 58 k Clearance 58 Confirms Receipt 58 Integrated Preclinical 58 Cancer Vaccines 58 Adjunctive Therapy 58 Paris IPN Euronext 58 HuCAL PLATINUM R 58 sublicensed 58 Settle Patent Dispute 58 Cancer Stem Cells 58 Advisers Urge 58 Dendrimer 58 ACTCellerate 58 Transdermal Delivery 58 Poster Presentations 58 Potential Dangers 58 Nasdaq VNDA 58 Milestone Achieved 58 Underwritten Public 58 Enters Into LOI 58 Bone Marrow Stem Cells 58 Combination Clinical Trial 58 Announces Definitive Merger 58 Announces Discontinuation 58 Spectrum Pharmaceuticals Announces 58 Demonstrates Statistically Significant 58 Fraunhofer CMB 58 Initiates Voluntary Recall 58 Anti Angiogenic 58 Spins Off 58 Innate Immune 58 TB Vaccine 58 Patients Suffering 58 Announce Early Termination 58 Buy Privately Held 58 Epidermal Growth Factor Receptor 58 Skin Cells 58 Adjuvant Treatment 58 Protein Interactions 58 Confirms Validity 58 Acquire Privately Held 58 Infected Patients 58 Mesothelioma Treatment 58 Inhaled Corticosteroids 58 Announces Stockholder Approval 58 Metabolic Disorder 58 BIOLASE Announces 58 Uracyst R Test 58 Clinical Trial Data 58 RNA Interference 58 RxKinetix 58 Trial Evaluating 58 Significantly Reduces 58 Dose Ranging Study 58 Pending Litigation 58 Shows Efficacy 58 Milestone Reached 58 Patent Infringement 58 Liver Toxicity 58 Inc Therapeutic Competitors 58 Transfection 58 Carboplatin Paclitaxel 58 Sign Definitive Merger 58 ProEthic Pharmaceuticals 58 Successful Outcome 58 Drilling Permit 58 Unsolicited Tender Offer 58 Thrombin topical Recombinant 58 Remain Listed 58 Action Lawsuit 58 Dramatically Increases 58 Nasdaq XTLB 58 Receives Shareholder Approval 58 StockSource.us Reports 58 Completes Purchase 58 NASDAQ Delisting Notice 58 Inflammatory Disease 58 Study Showed 58 Data Suggest 58 DTC Eligibility 58 Unsolicited Proposal From 58 RECOTHROM R 58 Commences Subsequent 58 Announce Shareholder Approval 58 Flu Vaccines 58 IIROC Resume 58 Patent Ruling 58 Clinical Trial Enrollment 58 Anti Angiogenesis 58 Chemoprevention 58 Protein Biomarkers 58 Glaucoma Treatment 58 Pivotal Trial 58 Treated Patients 58 Fancamp Announces 58 Ridaforolimus 58 Radilex TM 58 Favorable Ruling 58 Reacquisition 58 Anticancer Activity 58 Hsp# Inhibitor 58 Patent Invalid 58 Disease Modifying 58 Xcytrin R 58 Tablet Formulation 58 Ecallantide 58 Supply Agreements 58 Stockholders Approve Merger 58 Anticancer Agents 58 MBMI Closes 58 Important Milestone 58 Contrast Agents 58 Cross Licensing Agreement 58 Mitral Valve Repair 58 Arch Biopartners 58 KL4 Surfactant 58 Commence Trading 58 Is Well Tolerated 58 Signs Purchase Agreement 58 Idenix Novartis 58 Extends Offer 58 CYOE 58 Employment Inducement Awards 58 Clarifies Status 58 Fast Tracked 58 Genetic Disorder 58 Immunostimulatory 58 Completes Recapitalization 58 Regains NASDAQ 58 Vitamin D analogue 58 Executes Letter 58 HCV Protease Inhibitor 58 Noninvasive Prenatal 58 Patients Enrolled 58 Optical Imaging 58 Successfully Closes 58 Successfully Completes Tender Offer 58 Desvenlafaxine Succinate 58 CIMYM 58 Phase III Pivotal 58 OTCBB HNAB 58 Sustained Release 58 Long Term Lease 58 Nationwide Voluntary Recall 58 Therapeutic Antibodies 58 Announcement acc 58 Recurrent Breast Cancer 58 Integra LifeSciences Announces 58 Stem Cell Innovations 58 Artificial Skin 58 Convertible Debenture Financing 58 Identifies Significant 58 Inks License 58 Combination REOLYSIN R 58 Over Subscribed 58 Proposed Private Placement 58 RECOTHROM ® 58 Cytokine PharmaSciences 58 Formalizes 58 Catalyst Biosciences 58 Renegotiates 58 Hepatitis B Vaccine 58 Sangamo BioSciences Announces 58 Clears Path 58 Files Patents 58 Inks Pact 58 Completes Transaction 58 iPS Cells 58 Becomes Effective 58 Be Studied 58 Its Previously Announced 58 OTCBB FCSC 58 miRagen Therapeutics 58 Prophylactic Treatment 58 Double Blind Placebo 58 Enters Option Agreement 58 Improves Outcomes 58 Confirms Commitment 58 Completes Sale 58 Nanoparticle 58 Evaluate Strategic Alternatives 58 Completes Due Diligence 58 Reacquire 58 II Clinical Trial 58 Million Doses 58 Permanent Injunction 58 Asset Swap 58 Terminate Agreement 58 Oncolys 58 Enters Exclusive 58 Unresectable 58 Pulmonary Arterial Hypertension 58 Protein Therapeutics 57 Announce Joint Venture 57 Dendritic Nanotechnologies Inc. 57 Issues Guidance 57 Awarded Multi 57 FOLOTYN ® 57 Severe Sepsis 57 Progresses 57 Patent Portfolio 57 Distribution Agreements 57 Infringement Case 57 TapImmune Inc. 57 Prism Pharmaceuticals 57 License Agreement 57 Previously Treated 57 Rated Speculative Buy 57 Receives CE 57 Ucyclyd Pharma Inc. 57 Anti Nausea 57 Estrogen Therapy 57 Moves Towards 57 visit http:/www.mannkindcorp.com 57 MorphoSys proprietary 57 Commences Phase III 57 Founding Scientist 57 FDA Warns 57 Inflammatory Response 57 Announces Underwriters Exercise 57 Announcement Regarding 57 Announces Reverse Split 57 Receives Authorization 57 Prostate Cancer Patients 57 Announces Reverse Merger 57 Arranges Non Brokered 57 Reduces Debt 57 Awarded Prestigious 57 Enters Joint Venture 57 RNA Interference RNAi 57 Signaling Pathway 57 Oligonucleotides 57 Quark Pharmaceuticals 57 Underwriters Exercise 57 Immunosuppressant

Back to home page